Advertisement

ADVERTISEMENT

ALK NSCLC

Qing Zhou, MD, PhD
Conference Insider
Lorlatinib Superior To Crizotinib in ALK+ NSCLC
10/29/2021
Results from a subgroup analyses of the CROWN trial found first-line lorlatinib offered greater PFS benefit to crizotinib in Asian patients with ALK+ NSCLC.
Results from a subgroup analyses of the CROWN trial found first-line lorlatinib offered greater PFS benefit to crizotinib in Asian patients with ALK+ NSCLC.
Results from a subgroup analyses...
10/29/2021
Oncology
Didier Debieuvre
Conference Coverage
Real-World Data Shows Crizotinib is Effective Treating in ALK+ and ROS1+ NSCLC
10/27/2021
French patients with advanced NSCLC with ALK-positive or ROS1-positive gene rearrangement responded well to Crizotinib, according to real-world data presented at the 2021 ESMO Congress.
French patients with advanced NSCLC with ALK-positive or ROS1-positive gene rearrangement responded well to Crizotinib, according to real-world data presented at the 2021 ESMO Congress.
French patients with advanced...
10/27/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Superior in ALK+ NSCLC?
10/15/2021
True or false: Recent data from the ESMO Congress confirm crizotinib showed greater efficacy than brigatinib for patients with ALK TKI-naïve advanced ALK+ NSCLC.
True or false: Recent data from the ESMO Congress confirm crizotinib showed greater efficacy than brigatinib for patients with ALK TKI-naïve advanced ALK+ NSCLC.
True or false: Recent data from...
10/15/2021
Oncology
Test Your Knowledge
Quiz: Which of the Following is Not a Viable TKI for ALK+ NSCLC?
10/15/2021
Multiple choice: Which of the following is not a viable TKI to use after brigatinib discontinuation for patients with ALK+ NSCLC?
Multiple choice: Which of the following is not a viable TKI to use after brigatinib discontinuation for patients with ALK+ NSCLC?
Multiple choice: Which of the...
10/15/2021
Oncology
SP
Conference Coverage
Brigatinib Superior to Crizotinib in ALK NSCLC
09/22/2021
Final results from the ALTA-1L trial found that brigatinib demonstrated greater survival benefit than crizotinib in patients with ALK+ NSCLC.
Final results from the ALTA-1L trial found that brigatinib demonstrated greater survival benefit than crizotinib in patients with ALK+ NSCLC.
Final results from the ALTA-1L...
09/22/2021
Oncology
Conference Coverage
Brigatinib Yields Durable Benefit in ALK NSCLC
09/22/2021
In a recent study in ALK+ NSCLC, post-brigatinib statuses and TKI therapy was investigated to understand the clinical effects of brigatinib after treatment discontinuation.
In a recent study in ALK+ NSCLC, post-brigatinib statuses and TKI therapy was investigated to understand the clinical effects of brigatinib after treatment discontinuation.
In a recent study in ALK+ NSCLC,...
09/22/2021
Oncology
Conference Insider
Later Generation ALK Inhibitors Yield Encouraging Results in NSCLC
06/15/2021
According to results from a retrospective study presented at the virtual 2021 ASCO Annual Meeting, newer generations of ALK inhibitors demonstrated improved survival and blood-brain barrier penetration in NSCLC with brain metastases.
According to results from a retrospective study presented at the virtual 2021 ASCO Annual Meeting, newer generations of ALK inhibitors demonstrated improved survival and blood-brain barrier penetration in NSCLC with brain metastases.
According to results from a...
06/15/2021
Oncology
Conference Insider
Brigatinib Safe, Effective for Crizotinib-Refractory ALK+ NSCLC
06/03/2021
Findings from the ALTA trials show that brigatinib is effective, with manageable safety, in patients with crizotinib-refractory ALK+ NSCLC.
Findings from the ALTA trials show that brigatinib is effective, with manageable safety, in patients with crizotinib-refractory ALK+ NSCLC.
Findings from the ALTA trials...
06/03/2021
Oncology
Conference Insider
No Survival Benefit With Alectinib vs Crizotinib for ALK+ NSCLC
06/01/2021
According to the final J-ALEX OS analysis results, alectinib yielded no advantage in OS compared with crizotinib in patients with ALK+ NSCLC.
According to the final J-ALEX OS analysis results, alectinib yielded no advantage in OS compared with crizotinib in patients with ALK+ NSCLC.
According to the final J-ALEX OS...
06/01/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use